Lisata Therapeutics, Inc. - Common Stock (NQ:LSTA)

1.960 UNCHANGED

Streaming Delayed Price Updated: 3:16 PM EST, Nov 24, 2025 Add to My Watchlist

Price and Volume

Volume	20,139
Open	1.920
Bid (Size)	1.940 (700)
Ask (Size)	2.020 (600)
Prev. Close	1.960
Today's Range	1.920 - 1.990
52wk Range	1.810 - 4.200
Shares Outstanding	60,533,064
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Lisata Therapeutics (NASDAQ:LSTA) Reports Narrower-Than-Expected Q3 2025 Loss ↗

November 06, 2025

Lisata Therapeutics reported a narrower-than-expected Q3 2025 loss, advancing its lead candidate, certepetide, with a cash runway into 2027.

Via Chartmill

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 06, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-45.1%	-45.1%
1 Month	-16.6%	-16.6%
3 Month	-22.5%	-22.5%
6 Month	-23.8%	-23.8%
1 Year	-31.9%	-31.9%

More News

Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’

November 06, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 04, 2025

Via Benzinga

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

November 04, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

October 30, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

October 08, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

September 29, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 02, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 07, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025

July 31, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 21, 2025

Via Benzinga

Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update

July 17, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide

July 15, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer

June 26, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

June 17, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics to Present at the 2025 BIO International Convention

June 11, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 08, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025

May 01, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics Announces Research License with Catalent

April 15, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics to Present at the Investival Showcase USA

March 06, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

March 05, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Lisata Therapeutics, Inc. - Common Stock publicly traded?

Yes, Lisata Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Lisata Therapeutics, Inc. - Common Stock trade on?

Lisata Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Lisata Therapeutics, Inc. - Common Stock?

The ticker symbol for Lisata Therapeutics, Inc. - Common Stock is LSTA on the Nasdaq Stock Market

What is the current price of Lisata Therapeutics, Inc. - Common Stock?

The current price of Lisata Therapeutics, Inc. - Common Stock is 1.960

When was Lisata Therapeutics, Inc. - Common Stock last traded?

The last trade of Lisata Therapeutics, Inc. - Common Stock was at 11/24/25 03:16 PM ET

What is the market capitalization of Lisata Therapeutics, Inc. - Common Stock?

The market capitalization of Lisata Therapeutics, Inc. - Common Stock is 118.64M

How many shares of Lisata Therapeutics, Inc. - Common Stock are outstanding?

Lisata Therapeutics, Inc. - Common Stock has 119M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.